report
develop
immunoglobulin
igm
antibodi
captur
enzymelink
immunosorb
assay
macelisa
sever
acut
respiratori
syndrom
coronaviru
sarscov
use
recombin
truncat
sarscov
nucleocapsid
protein
antigen
newli
develop
macelisa
specif
sensit
evalu
use
sera
healthi
volunt
patient
laboratoryconfirm
sar
use
serial
serum
sampl
collect
sar
patient
time
seroconvers
determin
igm
antibodi
detect
sarscov
infect
median
time
seroconvers
detect
day
rang
day
diseas
onset
seroconvers
rate
onset
ill
first
week
second
week
third
week
compar
result
previou
report
detect
igg
median
seroconvers
time
igm
detect
day
earlier
seroconvers
rate
second
week
ill
igm
significantli
higher
igg
assay
result
indic
igm
respons
appear
earlier
igg
sarscov
infect
consist
pathogen
newli
develop
macelisa
system
offer
new
altern
confirm
sarscov
infect
sever
acut
respiratori
syndrom
sar
human
diseas
associ
pneumonia
emerg
recent
emerg
sar
coronaviru
sarscov
sever
report
deal
detect
specif
immunoglobulin
igm
indirect
enzymelink
immunosorb
assay
elisa
indirect
immunofluoresc
assay
ifa
studi
igm
antibodi
becam
detect
later
igg
antibodi
contrast
phenomena
describ
known
pathogen
reason
earlier
igg
respons
unclear
may
due
earlier
develop
igg
antibodi
igm
antibodi
altern
observ
may
reflect
low
sensit
assay
detect
igm
known
detect
igm
without
separ
igg
yield
higher
rate
falseposit
falseneg
result
therefor
serolog
respons
sarscovinfect
patient
examin
use
moresensit
method
antibodi
sarscov
nucleocapsid
protein
longerliv
occur
greater
abund
sar
patient
antibodi
viral
compon
spike
membran
envelop
protein
previou
studi
report
indirect
igg
elisa
base
ntermin
truncat
nucleocapsid
protein
safe
specif
sensit
test
diagnosi
sarscov
infect
data
indic
nucleocapsid
protein
sarscov
good
target
antigen
diagnosi
studi
develop
specif
sensit
igm
antibodi
captur
elisa
macelisa
sar
cov
use
recombin
truncat
sarscov
nucleocapsid
protein
antigen
macelisa
design
specif
detect
igmtyp
antibodi
sensit
specif
macelisa
assess
addit
use
serial
serum
sampl
collect
sar
patient
time
requir
patient
exhibit
igm
seroconvers
sarscov
infect
determin
compar
result
previou
studi
igg
detect
found
sarscov
infect
igm
respons
appear
earlier
igg
respons
resembl
host
respons
known
pathogen
serum
sampl
one
hundr
seventyf
serum
sampl
collect
healthi
volunt
hanoi
vietnam
sar
outbreak
use
neg
serum
control
serial
serum
sampl
patient
laboratoryconfirm
sar
french
hospit
hanoi
vietnam
collect
march
april
sera
heat
inactiv
min
use
protein
prepar
sarscov
protein
encompass
amino
acid
residu
nucleocapsid
protein
n
protein
construct
amino
acid
n
terminu
truncat
express
purifi
describ
previous
protein
use
anim
immun
well
antigen
macelisa
product
hyperimmun
mous
ascit
fluid
threeweekold
balbc
mice
inject
intraperiton
l
g
purifi
protein
emulsifi
equal
volum
freund
complet
adjuv
mp
biomed
two
booster
inject
given
dose
protein
freund
incomplet
adjuv
mp
biomed
interv
one
week
final
booster
inject
myeloma
cell
inject
intraperiton
ascit
fluid
collect
indirect
igg
elisa
indirect
igg
elisa
base
recombin
truncat
sarscov
protein
describ
previous
igm
captur
elisa
procedur
sarscovspecif
igm
test
done
coat
well
immunopl
goat
antihuman
igm
antibodi
ad
patient
control
sera
antiigmco
well
allow
captur
igm
react
recombin
sarscov
protein
captur
sarscov
protein
detect
sarscov
viru
hyperimmun
mous
ascit
fluid
bound
protein
antibodi
detect
horseradish
peroxidaseconjug
antimous
igg
follow
h
abt
acid
substrat
optim
dilut
reagent
determin
checkerboard
titrat
refer
sera
refer
sera
select
accord
preliminari
experiment
result
serum
avail
refer
sera
use
inner
control
assay
actual
procedur
follow
ninetysixwel
falcon
immunopl
becton
dickinson
coat
l
dilut
goat
antihuman
igm
biosourc
intern
dilut
phosphatebuff
salin
pb
ph
plate
coat
conduct
overnight
plate
wash
five
time
pbst
pb
plu
tween
allow
react
patient
serum
patient
serum
sampl
dilut
dilut
assay
diluent
pbst
plu
skim
milk
patient
serum
ad
four
well
plate
patient
sampl
incub
plate
h
follow
wash
antigen
purifi
recombin
truncat
sarscov
protein
ad
concentr
g
assay
diluent
upper
two
well
assay
diluent
ad
lower
two
well
neg
control
plate
incub
h
plate
wash
dilut
antisar
cov
protein
hyperimmun
mous
polyclon
ascit
fluid
ad
incub
h
plate
wash
dilut
goat
antimous
igghorseradish
peroxidas
conjug
biosourc
ca
ad
mixtur
incub
h
plate
wash
l
abtsperoxidas
substrat
kirkegaard
perri
laboratori
ad
plate
incub
dark
min
optic
densiti
od
measur
nm
specif
activ
serum
net
od
calcul
subtract
nonspecif
background
od
well
without
antigen
specif
od
well
sarscov
protein
antigen
valu
report
repres
averag
result
duplic
well
sampl
test
plate
dilut
neg
control
weakli
posit
control
od
posit
sampl
od
neg
control
pn
approxim
equal
strongli
posit
control
pn
serum
sampl
run
simultan
neg
control
one
blood
sampl
healthi
subject
od
valu
control
establish
mean
od
sarsneg
subject
plu
standard
deviat
sampl
test
duplic
mean
od
sampl
calcul
cutoff
assay
twice
mean
od
neg
control
serum
sampl
pn
specif
macelisa
estim
use
sera
collect
healthi
volunt
hanoi
vietnam
sar
outbreak
serum
sampl
found
nonreact
newli
develop
sarscov
macelisa
specif
sarscov
macelisa
sensit
macelisa
sarscov
use
recombin
truncat
n
protein
determin
sensit
macelisa
serum
sampl
serial
collect
patient
laboratoryconfirm
sar
vietnam
investig
reactiv
patient
sera
found
reactiv
newli
develop
macelisa
sensit
sarscov
macelisa
reproduc
macelisa
result
sarscov
use
recombin
truncat
n
protein
control
serum
od
stabl
differ
plate
test
time
also
differ
test
time
neg
control
serum
alway
neg
od
variat
weakli
strongli
posit
control
sera
less
differ
assay
time
comparison
seroconvers
time
seroconvers
rate
time
detect
proteinbas
igg
elisa
macelisa
time
seroconvers
patient
serial
serum
sampl
collect
shown
tabl
igm
detect
median
time
seroconvers
day
rang
day
diseas
onset
igg
detect
median
time
seroconvers
day
rang
day
diseas
onset
seroconvers
rate
time
onset
ill
detect
proteinbas
igg
elisa
macelisa
patient
serial
serum
sampl
collect
shown
tabl
igg
detect
protein
igg
seroconvers
rate
onset
ill
first
week
second
week
third
week
igm
detect
protein
igm
seroconvers
rate
onset
ill
first
week
second
week
third
week
igm
seroconvers
rate
second
week
ill
significantli
higher
observ
igg
p
igm
antibodi
produc
earli
immun
respons
rise
rapidli
diseas
cours
henc
detect
igm
antibodi
valuabl
tool
rapid
diagnosi
acut
viral
infect
macelisa
design
specif
igm
captur
format
macelisa
elimin
potenti
background
caus
extran
antibodi
turn
result
less
frequent
nonspecif
reaction
well
absenc
falseposit
result
march
guest
http
cviasmorg
caus
rheumatoid
factor
competit
igm
igg
antigen
bind
minim
reduc
occurr
falseneg
result
thu
allow
morereli
sensit
detect
igm
antibodi
antigen
emerg
sarscov
sever
studi
deal
detect
specif
igm
antibodi
use
indirect
elisa
ifa
method
report
woo
et
al
report
igm
antibodi
becam
detect
later
igg
antibodi
indirect
elisa
ifa
hsueh
et
al
report
igg
seroconvers
occur
simultan
day
earlier
igm
seroconvers
ifa
absorb
igg
detect
igm
avoid
interfer
igg
antibodi
chang
et
al
also
report
similar
igg
igm
subclass
respons
sarscov
infect
studi
igm
antibodi
becam
detect
later
simultan
igg
antibodi
contrast
phenomena
describ
known
pathogen
igm
antibodi
often
appear
day
earlier
igg
antibodi
known
detect
igm
antibodi
without
separ
igg
antibodi
yield
higher
rate
falseposit
falseneg
result
henc
reason
earlier
igg
respons
observ
studi
mention
may
low
sensit
assay
system
detect
igm
rather
biolog
host
immun
respons
use
recombin
truncat
sarscov
nucleocapsid
protein
antigen
develop
igm
captur
elisa
system
sarscov
newli
develop
macelisa
specif
sensit
evalu
use
sera
healthi
volunt
patient
laboratoryconfirm
sar
indic
assay
system
sensit
reliabl
newli
develop
macelisa
system
first
report
igm
captur
assay
sarscov
use
recombin
protein
offer
one
choic
serolog
diagnosi
sar
use
serial
serum
sampl
collect
patient
laboratoryconfirm
sar
compar
igm
igg
antibodi
seroconvers
time
sarscov
infect
igm
antibodi
median
time
seroconvers
detect
day
diseas
onset
seroconvers
rate
onset
ill
first
week
second
week
third
week
igg
antibodi
median
time
seroconvers
detect
day
diseas
onset
igg
seroconvers
rate
onset
ill
first
week
second
week
third
week
mean
seroconvers
time
igm
day
earlier
igg
addit
rate
posit
igm
significantli
higher
igg
second
week
onset
ill
result
indic
igm
respons
appear
earlier
igg
respons
sarscov
infect
consist
phenomena
observ
known
pathogen
igm
antibodi
often
appear
day
earlier
igg
antibodi
result
suggest
earlier
igg
igm
respons
previous
report
research
might
due
low
sensit
test
system
employ
rather
repres
actual
time
igmtoigg
switch
result
present
combin
former
report
clearli
indic
recombin
truncat
sarscov
nucleocapsid
protein
good
target
antigen
sar
diagnosi
result
highli
reproduc
newli
develop
system
use
infecti
viru
antigen
product
requir
high
level
microbiolog
secur
proper
way
inactiv
monitor
inactiv
process
viru
requir
henc
safer
method
diagnosi
advantag
use
prokaryot
host
produc
recombin
protein
would
consider
due
eas
scaleup
low
cost
involv
grow
bacteria
recombin
product
obtain
within
rel
short
time
within
week
clone
express
purif
procedur
simpl
easi
perform
liter
cultur
bacteri
medium
obtain
mg
purifi
protein
method
would
much
less
expens
prepar
antigen
use
virusinfect
cell
cultur
eukaryot
express
system
would
especi
use
develop
countri
well
case
largescal
epidemiolog
investig
